Potential Target For Ulcerative Colitis Drugs by Pooja Shete on January 15, 2021 at 7:36 PM
The study conducted by researchers from Cleveland Clinic s Lerner Research Institute is published in the journal
Nature Communications.
The researchers used this model to identify a promising target that could be blocked to slow the disease progression. Ulcerative colitis occurs due to abnormal reactions of the immune system that lead to inflammation and ulcers on the inner lining of the large intestines. The condition is highly heterogeneous both in terms of patients symptoms and disease pathology.
Current therapy for ulcerative colitis mainly focuses on suppressing the overactive immune response with anti-inflammatory drugs. However, these therapies have limited long-term efficacy in ulcerative colitis patients.